Novynette

Quick links to important sections

Novynette

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novynette

Property Description
Active Ingredients Desogestrel and Ethinyl Estradiol
Form Monophasic film-coated tablet
Pharmacological Class Hormonal Contraceptive (Combination)
Common Use Systemic pregnancy prevention
Origin Synthetic (chemically manufactured)

Novynette is defined as a combination oral contraceptive (COC), a prescription-only medicine classified within the high-level pharmacological group of Hormonal Contraceptives, primarily used for systemic hormonal contraception to prevent pregnancy. As a synthetic product, Novynette offers a reliable method for regulating the female reproductive cycle, a characteristic recognized in clinical and pharmacological contexts. This product is structurally similar to other Desogestrel and Ethinyl Estradiol formulations, such as Marvelon, and is manufactured by Gedeon Richter.

Composition and Form: Desogestrel and Ethinyl Estradiol

Novynette is a combination product because its therapeutic effect relies on two distinct synthetic hormonal agents: Desogestrel, which is a progestogen, and Ethinyl Estradiol, which is an estrogen. This medication is typically presented as a monophasic film-coated tablet designed for oral administration. The monophasic nature signifies that every active tablet in the pack contains the same consistent dosage of both the Desogestrel and the Ethinyl Estradiol components throughout the 21-day regimen. The synthetic origin of these hormones allows them to mimic the body's natural hormones to achieve their intended purpose.

General Purpose: Triple-Action Contraception

The core purpose of Novynette is to achieve effective pregnancy prevention through coordinated physiological actions. The hormones function primarily to signal the body to halt the maturation and release of an egg, an effect known as ovulation inhibition. Based on pharmacological properties, the combination of hormones works to alter the consistency of the cervical mucus, thickening it to impede sperm movement, and induce subtle changes in the uterine lining. These mechanisms work synergistically, providing a continuous form of systemic contraception.

Regulatory References

  1. MedlinePlus Birth Control Information

What side effects are possible with Novynette?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Novynette (Desogestrel and Ethinyl Estradiol), as classified by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on regulatory standards:

  • Common (1% to 10%): The most frequently reported adverse effects include headache, nausea, vomiting, depressed mood or mood changes, breast pain/tenderness, abdominal pain, and an increase in body weight.
  • Uncommon (0.1% to 1%): Effects documented less often include fluid retention, migraine, diarrhea, decreased libido, nervousness, skin rash, and urticaria (hives).
  • Rare (0.01% to 0.1%): Reactions classified as rare include hypersensitivity, changes in body weight, increased libido, intolerance to contact lenses, and certain severe skin reactions like erythema nodosum.

Serious Safety Considerations

The regulatory profile explicitly documents the risk of thromboembolic events, which are rare but clinically serious. These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Arterial Thromboembolism (ATE), such as stroke and myocardial infarction. Other rare serious safety concerns include the development of Hepatic Neoplasia (liver tumors, benign or malignant) and significant Hypertension.

Time- and Population-Related Safety Patterns

The official labeling notes that the highest risk of VTE is documented during the first year of use or when restarting after a break of four weeks or more. Furthermore, the risk of serious cardiovascular events is markedly increased in women who smoke and are over 35 years of age, a key safety restriction. Novynette is contraindicated in women with a history of thromboembolic disorders or severe hepatic disease.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for combination oral contraceptives define the overdose profile primarily by expected acute hormonal effects, which are not expected to be life-threatening or associated with serious adverse outcomes. The severity of acute overdose is generally low based on official regulatory classifications.

Documented Overdose Manifestations

Ingestion of an excessive number of tablets may result in predictable clinical manifestations, predominantly nausea and vomiting, affecting the gastrointestinal system. A key manifestation noted across regulatory sources is withdrawal bleeding (vaginal bleeding), resulting from the hormonal effects on the reproductive system. This specific presentation has been documented to occur even in young females, including pre-pubertal girls, following high ingestion.

Official Emergency Actions and Management

In the event of a suspected overdose, regulatory guidance mandates that individuals seek immediate medical attention and/or contact a certified poison control center for guidance. Management is officially restricted to symptomatic and supportive treatment within a clinical setting, as no specific antidote is known for this combination formulation. Clinical evaluation may include the monitoring of vital signs and necessary laboratory assessments.

Therapeutic Uses of Novynette

Quick Facts

  • Primary Use: Prevents pregnancy in women of reproductive potential.
  • Associated Benefits: May help manage menstrual cycle regularity and reduce the experience of dysmenorrhea (menstrual pain).

Novynette is a combination oral contraceptive prescribed to prevent pregnancy (contraception). It is a recognized and established option for managing reproductive planning, offering an effective method when used as directed.

Beyond its primary indication, clinical evidence suggests that using this combination formulation may be associated with certain non-contraceptive health benefits. These include supporting the establishment of predictable menstrual cycles and contributing to the reduction of discomfort often related to menstruation, such as menstrual pain (dysmenorrhea).

Furthermore, combination oral contraceptives like Novynette have been investigated for a potential decrease in the incidence of ovarian and endometrial cancers with prolonged use. The full scope of its therapeutic profile and benefits is established for formulations containing desogestrel and ethinyl estradiol.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Novynette

The medicine is indicated for systemic pregnancy prevention in women of reproductive potential, including adolescents who have reached menarche. However, official regulatory documents define strict non-eligibility rules based on specific medical and physiological states.

Scope Item Official Regulatory Statement
Populations for whom use is allowed Women of reproductive potential for pregnancy prevention.
Populations for whom use is not recommended Women who are breastfeeding/lactating [Regulatory Source].
Populations for whom use is contraindicated Females with current or past thromboembolic disorders (e.g., DVT, PE), coronary artery disease, cerebral vascular disease, severe uncontrolled hypertension, estrogen-dependent neoplasia (e.g., breast cancer), hepatic tumors, or active liver disease [Regulatory Source].

Age-Related Eligibility Rules

  • Pediatric/Adolescent: Should not be used before the start of menstruation (menarche) [Regulatory Source].
  • Geriatric: Not indicated for use in postmenopausal women or the elderly [Regulatory Source].

Eligibility-Related Restrictions

  • The medicine must not be used by females over 35 years of age who smoke [Regulatory Source].
  • Use is prohibited in cases of known or suspected pregnancy [Regulatory Source].
  • Use must be discontinued before and after major surgery or periods of prolonged immobilization [Regulatory Source].

What should I know about interactions with other medicines?

Novynette, a combination oral contraceptive containing desogestrel and ethinyl estradiol, has officially documented interactions that may impact its systemic exposure or safety profile, as outlined in regulatory labeling.

Contraindicated Combinations

Co-administration with specific Hepatitis C combination regimens, such as those containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is formally contraindicated due to the risk of liver enzyme (ALT) elevation. Additionally, cigarette smoking is a formal contraindication for females over 35 years of age due to the significantly increased risk of serious cardiovascular events.

Interactions Affecting Exposure

Substances that induce CYP enzymes (e.g., certain anticonvulsants, Rifampicin, and the herbal product St. John’s Wort) are documented to decrease the systemic concentration of the hormonal components, which can reduce contraceptive efficacy. Conversely, substances that inhibit hormone metabolism (e.g., certain antifungals, Grapefruit Juice) may increase the plasma levels of ethinyl estradiol.

Timing and Procedural Constraints

Formal timing rules are mandated for certain co-administrations; for instance, the contraceptive must be discontinued before starting the contraindicated Hepatitis C therapy and restarted approximately 2 weeks after completion. Furthermore, the combination must be discontinued at least 4 weeks prior to and through 2 weeks after major surgery due to the elevated risk of venous thromboembolism.

Mechanism of Action

Mechanism of Action: Hormonal Pathway Modulation

Novynette, a combined hormonal agent, acts primarily by modulating core endocrine regulatory systems. Its active components, ethinylestradiol and the active metabolite etonogestrel (formed from the prodrug desogestrel), exert systemic effects via receptor-mediated signaling.

The principal mechanistic domain involves engaging in negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. This interaction suppresses the release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus and, consequently, the pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This cascade results in the inhibition of follicular maturation and ovulation.

Auxiliary mechanisms involve the peripheral effects of etonogestrel. It alters the secretory function of the cervical glands, causing the cervical mucus to thicken and exhibit reduced permeability to sperm. Additionally, it modulates the developmental state of the endometrium (uterine lining), contributing to a modified physiological state of the reproductive tract.

Dosage and Administration Information

How to Use Novynette: Administration Guidelines

Novynette is administered orally as a monophasic film-coated tablet containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. The administration protocol is established to ensure consistent systemic hormone delivery.


Standard Dosing and Cyclic Schedule

The standard adult regimen requires taking one active tablet per day for 21 consecutive days, followed by a 7-day tablet-free interval. This defines the standard 21/7 cyclic regimen. The tablet must be taken at approximately the same time each day, a procedural requirement to maintain steady hormone levels. Initiation of the first pack is typically recommended on Day 1 of the menstrual cycle, though starting on days 2–5 is permissible, provided a non-hormonal barrier method is used for the first seven days of active tablet intake.


Administration Conditions and Procedural Rules

Tablets should be swallowed whole with water and may be taken with or without food. If vomiting or severe diarrhea occurs within 3-4 hours of administration, the event is classified as a missed dose, and subsequent procedural rules must be followed.

In the event of missed timing, a tablet missed by less than 12 hours must be taken immediately, with the standard schedule continuing thereafter. If the omission exceeds 12 hours, contraceptive protection is considered reduced, necessitating the immediate use of a non-hormonal backup method for the following seven days, in addition to continuing the pack. The cycle may be immediately continued with a new pack, skipping the 7-day tablet-free interval, if the postponement of withdrawal bleeding is desired.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Novynette


Research Context for Contraceptive Use

Research explored the effectiveness of combination oral contraceptives, such as the formulation in Novynette, evaluated extensively using a combination of Randomized Controlled Trials (RCTs) and large-scale observational cohort studies. Research explored the ability to manage reproductive planning, which is the core context of its use. These studies monitored the number of unintended pregnancies across large groups of women over time, often calculating the Pearl Index to quantify contraceptive failure rates. Studies included generally healthy women of reproductive potential, primarily adults, and post-menarche adolescents.

Findings describe patterns observed in these studies, which consistently report Pearl Index measurements corresponding to the study's goal of measuring contraceptive failure rates when the medication is used exactly as prescribed. However, results apply only to the populations studied, and the measurements of efficacy are sensitive to whether the regimen is followed consistently; study outcomes reflect effectiveness achieved under the specific conditions of the study.


Research on Associated Menstrual Cycle Characteristics

Research has explored whether patterns in the menstrual cycle, including symptoms, were altered during the study period. Studies monitored patient-reported outcomes describing perceived discomfort. Researchers examined the intensity of menstrual pain (dysmenorrhea), using standardized pain scores. Research also described patterns in the consistency and predictability of the menstrual cycle length while using the pill.

Outcomes related to physical discomfort are substantially patient-reported and subjective, which means findings were mixed or varied across studies depending on the specific hormonal dose and study population. Comparative evidence is lacking for how this specific formulation compares against non-hormonal treatments designed specifically for dysmenorrhea.


What Remains Uncertain and Areas for Future Research

Research highlights what is known—and what is still uncertain—about this medication. A key limitation is that efficacy is highly dependent on consistent adherence to the regimen, and research does not fully capture failure rates resulting from non-adherence to the dosing schedule. Furthermore, the evidence related to certain non-contraceptive patterns comes primarily from observational research (where women are not randomly assigned), and the methodology does not establish a definitive causal link.

Frequently Asked Questions (FAQ)

Common questions about Novynette (FAQ)

Q: Is Novynette the same as other 'mini-pills'?

Novynette is officially classified as a combination oral contraceptive. This means it contains two types of hormones (estrogen and a progestogen). In contrast, a 'mini-pill' contains only a progestogen hormone. Official drug classification relies on the combination of these two components.

Q: What is Novynette primarily used for?

The primary purpose of Novynette is systemic pregnancy prevention, as described in official indications. Official documents also note that this class of combination pills can be associated with other patterns, such as regulating the menstrual cycle and sometimes improving acne.

Q: How does the combination of hormones in Novynette work?

The medication works primarily by stopping the release of an egg from the ovary, which is called the inhibition of ovulation. This action is supported by secondary effects, such as thickening the cervical mucus, which contributes to impeding sperm movement.

Q: How long does it typically take for Novynette to 'work'?

Official administration rules provide guidance on when contraceptive protection is established. When starting the medication outside of the first day of the menstrual cycle, a backup barrier method is typically advised for the first seven days of continuous active tablet intake to support consistent hormone levels and established contraceptive effectiveness.

Q: Does Novynette interact with antibiotics?

Official regulatory documents indicate that only a specific class of antibiotics, known as rifamycins (such as Rifampicin), are formally documented to reduce the medication's effectiveness by increasing hormone metabolism. Most other common antibiotics are not documented to cause this interaction.

Q: Are there any herbal supplements that interact with Novynette?

Yes, regulatory documents specifically mention the herbal supplement St. John’s Wort as a substance that may reduce the effectiveness of the hormonal components. This interaction is described as speeding up the metabolism of the active ingredients, which can reduce their presence in the body.

Q: Does Novynette affect the effectiveness of other medications?

Yes, official safety information states that the hormonal components may affect the way certain other medicines work in the body, potentially making them less effective. An example of a medicine known to be affected is lamotrigine.

Q: What should be done if vomiting occurs after taking Novynette?

According to official administration rules, if vomiting occurs within 3 to 4 hours of taking an active tablet, the event is classified as a missed dose. When this occurs, taking a replacement tablet immediately is the procedural guidance designed to maintain continuous hormone delivery.

Q: Can Novynette affect future fertility?

Official information indicates that the changes caused by the medication are temporary. The contraceptive effects are designed to be fully reversible after the medication is stopped, and official information supports this intended reversibility.

Q: What happens if you switch to Novynette from a different pill?

The procedure documented for switching from another combined pill involves starting Novynette on the day immediately following the last active tablet of the previous pill. This protocol is intended to maintain continuous hormone exposure, as outlined in regulatory documents.

Q: Does Novynette affect cholesterol levels?

Official research has examined the effect of the medication on blood fats (lipids). Findings consistently show that the use of this specific formulation may lead to an increase in the blood levels of a specific type of fat called triglycerides.

Q: What does official data say about the risk of breast cancer with Novynette?

Regulatory documents describe that a small, temporary increase in the risk of breast cancer has been observed in women who use combined oral contraceptives. This observed risk is noted to reduce gradually once the medication is stopped.

Q: Does Novynette help with heavy periods?

Official information indicates that, in addition to pregnancy prevention, the use of this class of medication is associated with a change in menstrual cycle patterns. This change often includes a lighter and more regular withdrawal bleed, which can be a secondary benefit.

Q: Can Novynette be used to help with acne?

Although the main purpose is contraception, the hormones in this class of medication are often associated with changes in skin health. Some regulatory labels for this type of medication acknowledge its use in managing moderate acne, which is a common application of combination pills.

Q: Is it normal to have spotting when starting Novynette?

Yes, official documents describe that some users may experience breakthrough bleeding or spotting, especially during the initial three cycles of starting the medication. This pattern is frequently reported as the body adjusts to the hormonal regimen.

Q: Do you always get a withdrawal bleed while taking Novynette?

No, a withdrawal bleed is not guaranteed. The bleed is expected to occur during the 7-day tablet-free interval. However, if the active tablets are taken continuously without a break to postpone the bleed, official documents state that the withdrawal bleeding will not occur.

Q: Do the side effects of Novynette usually go away after a few months?

Official information notes that adverse reactions such as spotting or nausea are often observed most frequently during the initial cycles of treatment. This pattern suggests that the body typically adjusts over the first few months of use.

Q: Can Novynette affect your mood or emotional state?

Yes, regulatory documents list mood changes, including depressed mood, feelings of nervousness, and changes in emotional state, as officially documented side effects reported by some users of hormonal contraceptives.

Q: Are there any major long-term studies on the use of Novynette?

Safety statements and research overviews in official documents often refer to findings observed in long-term users of combined oral contraceptives. These references typically relate to observations regarding the risk of certain cancers, suggesting the existence of long-term epidemiological studies for this class of medication.

Q: Can Novynette cause changes in libido?

Official documents list changes in libido (sex drive) as a reported adverse reaction. Specifically, both decreased libido is listed as an uncommon adverse reaction, and increased libido is listed as a rare adverse reaction.

Q: Is it true that Novynette may increase the risk of blood clots?

Yes, regulatory documents explicitly state that the use of combined hormonal contraceptives is associated with a small but serious risk of thromboembolic events, commonly known as blood clots. These include Deep Vein Thrombosis (DVT) and other serious vascular events.

Q: Does Novynette offer protection against any sexually transmitted infections?

No. Official regulatory and health agency documents confirm that Novynette provides systemic pregnancy prevention but does not offer any protection against Sexually Transmitted Infections (STIs).

Q: Can the effectiveness of Novynette be reduced by certain foods or drinks?

Yes, the regulatory documents note that consuming large amounts of Grapefruit Juice may potentially interact with the medication. This interaction may lead to an increase in the blood levels of the estrogen component.

Q: Does being overweight influence the effectiveness of Novynette?

Research overviews indicate that a woman's body weight or body mass index may potentially affect how the hormones in oral contraceptives are processed (metabolism). This is a factor that is often noted in clinical practice.

Q: What is the expiration time frame for an unopened pack of Novynette?

The medication should not be used past the expiration date printed on the original packaging. Official storage guidelines dictate that any unused or expired medication must be disposed of according to local pharmaceutical waste requirements.

Q: Is Novynette considered a 'monophasic' pill?

Yes, Novynette is officially classified as a monophasic pill. This means every active tablet in the pack contains the same, consistent dose of both the desogestrel and ethinyl estradiol components.

Q: Is it required to have a physical exam before starting Novynette?

Regulatory documentation states that a full medical history and physical examination are necessary parts of the required screening before the medication is started. This typically includes checking blood pressure and assessing the risk history for blood clots.

Q: Does the time of day you take Novynette matter?

Yes, official instructions state that the active tablet must be taken at approximately the same time each day. This is a procedural requirement intended to maintain steady hormone levels in the body and ensure consistent contraceptive effectiveness.

Q: Are there any specific organs Novynette is known to affect?

Regulatory documents contain specific warnings and safety information regarding the medication's effects on several organ systems. These include the cardiovascular system (related to blood clots), liver function, and blood pressure.

Q: Can Novynette cause changes in body weight?

Yes, official data lists changes in body weight as an officially reported adverse reaction. An increase in body weight is listed as a common adverse reaction, while other changes in body weight are reported as less common.

Q: Can Novynette cause changes in the skin/hair?

Regulatory documents list changes in the skin as officially reported adverse reactions. These include the appearance of rashes, hives (urticaria), and certain types of skin inflammation (erythema nodosum).

How should Novynette be stored and disposed of?

Storage and Disposal Requirements

Novynette (Desogestrel and Ethinyl Estradiol) must be stored strictly according to the conditions defined in the official regulatory labeling to ensure product stability.

Official Storage Conditions

The medicine must be stored at a temperature that does not exceed 25°C. To maintain the integrity of the film-coated tablets, the product must be protected from light and should not be removed from its original outer carton until required for use. As a critical safety measure, Novynette must always be kept out of the sight and reach of children.

Disposal

There are no special requirements for disposal beyond general regulatory guidelines. Any unused or expired Novynette must be disposed of according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novynette found in:

A-Z Index: